FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011815192> ?p ?o ?g. }

• W2011815192 endingPage "52" @default.
• W2011815192 startingPage "48" @default.
• W2011815192 abstract "Objective. Conservative surgery followed by platinum-based chemotherapy is considered the standard approach for stage I immature ovarian teratoma (IT), except for stage IA G1. Nevertheless the use of chemotherapy in stage IA G2–3 and IB–IC is controversial. The aim of this study was to evaluate the outcome of patients with IT in order to define the role of chemotherapy in stage I disease. Methods. Twenty-eight patients with stage I IT treated in MITO centers were retrospectively reviewed. Grade, stage, age, surgical and postoperative treatment were analyzed using χ2 test and T test looking for association with recurrence. Results. Median age was 25.5. Twenty-four patients underwent fertility-sparing surgery. FIGO stages were 19 IA, 2 IB, and 7 IC. Nine patients had grade 1 tumor, 12 grade 2, and 7 grade 3. Nine patients received adjuvant chemotherapy. Overall recurrence rate was 21.4% (2 in chemotherapy group and 4 in the group without treatment). No patients with G1 had recurrence, whereas 25% of G2 and 42.9% of G3 relapsed. Recurrence rate was not significantly different according to stage, grade or adjuvant chemotherapy, whereas it was greater in the group not operated in a MITO center, not staged and of age lower than 20 years, with statistical significance. At recurrence 4 patients presenting with mature teratoma were treated with surgery alone, whereas 2 recurring with IT were treated with surgery plus chemotherapy. After a median follow-up of 59 months all patients are NED. Conclusions. Our study suggests that chemotherapy may be withheld for primary therapy and utilized only for recurrence." @default.
• W2011815192 created "2016-06-24" @default.
• W2011815192 creator A5002158178 @default.
• W2011815192 creator A5024767033 @default.
• W2011815192 creator A5030229940 @default.
• W2011815192 creator A5038823610 @default.
• W2011815192 creator A5042255432 @default.
• W2011815192 creator A5052040098 @default.
• W2011815192 creator A5061939825 @default.
• W2011815192 creator A5074527671 @default.
• W2011815192 creator A5079315904 @default.
• W2011815192 creator A5086858324 @default.
• W2011815192 date "2010-10-01" @default.
• W2011815192 modified "2023-10-14" @default.
• W2011815192 title "Is adjuvant chemotherapy indicated in stage I pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian cancer (MITO-9)" @default.
• W2011815192 cites W1512761768 @default.
• W2011815192 cites W1835512930 @default.
• W2011815192 cites W1927592386 @default.
• W2011815192 cites W1974782744 @default.
• W2011815192 cites W1975002960 @default.
• W2011815192 cites W1995973513 @default.
• W2011815192 cites W1999568285 @default.
• W2011815192 cites W2005056331 @default.
• W2011815192 cites W2005285148 @default.
• W2011815192 cites W2006595774 @default.
• W2011815192 cites W2028018692 @default.
• W2011815192 cites W2032870251 @default.
• W2011815192 cites W2043110212 @default.
• W2011815192 cites W2062678919 @default.
• W2011815192 cites W2073072653 @default.
• W2011815192 cites W2075106628 @default.
• W2011815192 cites W2077980843 @default.
• W2011815192 cites W2081848324 @default.
• W2011815192 cites W2084469113 @default.
• W2011815192 cites W2091574730 @default.
• W2011815192 cites W2093254716 @default.
• W2011815192 cites W2109175854 @default.
• W2011815192 cites W2130803751 @default.
• W2011815192 cites W2141821404 @default.
• W2011815192 cites W2150626527 @default.
• W2011815192 cites W2267487266 @default.
• W2011815192 cites W3012730343 @default.
• W2011815192 cites W3139845394 @default.
• W2011815192 cites W4235639779 @default.
• W2011815192 cites W4255602882 @default.
• W2011815192 doi "https://doi.org/10.1016/j.ygyno.2010.05.035" @default.
• W2011815192 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20599258" @default.
• W2011815192 hasPublicationYear "2010" @default.
• W2011815192 type Work @default.
• W2011815192 sameAs 2011815192 @default.
• W2011815192 citedByCount "70" @default.
• W2011815192 countsByYear W20118151922012 @default.
• W2011815192 countsByYear W20118151922013 @default.
• W2011815192 countsByYear W20118151922014 @default.
• W2011815192 countsByYear W20118151922015 @default.
• W2011815192 countsByYear W20118151922016 @default.
• W2011815192 countsByYear W20118151922017 @default.
• W2011815192 countsByYear W20118151922018 @default.
• W2011815192 countsByYear W20118151922019 @default.
• W2011815192 countsByYear W20118151922020 @default.
• W2011815192 countsByYear W20118151922021 @default.
• W2011815192 countsByYear W20118151922022 @default.
• W2011815192 countsByYear W20118151922023 @default.
• W2011815192 crossrefType "journal-article" @default.
• W2011815192 hasAuthorship W2011815192A5002158178 @default.
• W2011815192 hasAuthorship W2011815192A5024767033 @default.
• W2011815192 hasAuthorship W2011815192A5030229940 @default.
• W2011815192 hasAuthorship W2011815192A5038823610 @default.
• W2011815192 hasAuthorship W2011815192A5042255432 @default.
• W2011815192 hasAuthorship W2011815192A5052040098 @default.
• W2011815192 hasAuthorship W2011815192A5061939825 @default.
• W2011815192 hasAuthorship W2011815192A5074527671 @default.
• W2011815192 hasAuthorship W2011815192A5079315904 @default.
• W2011815192 hasAuthorship W2011815192A5086858324 @default.
• W2011815192 hasConcept C121608353 @default.
• W2011815192 hasConcept C126322002 @default.
• W2011815192 hasConcept C141071460 @default.
• W2011815192 hasConcept C146357865 @default.
• W2011815192 hasConcept C151730666 @default.
• W2011815192 hasConcept C2776694085 @default.
• W2011815192 hasConcept C2776938808 @default.
• W2011815192 hasConcept C2778889167 @default.
• W2011815192 hasConcept C2780427987 @default.
• W2011815192 hasConcept C71924100 @default.
• W2011815192 hasConcept C86803240 @default.
• W2011815192 hasConceptScore W2011815192C121608353 @default.
• W2011815192 hasConceptScore W2011815192C126322002 @default.
• W2011815192 hasConceptScore W2011815192C141071460 @default.
• W2011815192 hasConceptScore W2011815192C146357865 @default.
• W2011815192 hasConceptScore W2011815192C151730666 @default.
• W2011815192 hasConceptScore W2011815192C2776694085 @default.
• W2011815192 hasConceptScore W2011815192C2776938808 @default.
• W2011815192 hasConceptScore W2011815192C2778889167 @default.
• W2011815192 hasConceptScore W2011815192C2780427987 @default.
• W2011815192 hasConceptScore W2011815192C71924100 @default.
• W2011815192 hasConceptScore W2011815192C86803240 @default.
• W2011815192 hasIssue "1" @default.
• W2011815192 hasLocation W20118151921 @default.

• next